尿液突变标志物用于膀胱癌诊断的系统综述
该系统综述汇总了截至2019年10月31日的25项研究,定性分析尿液膀胱癌突变标志物的诊断准确性,分别评估原发膀胱癌检测和膀胱癌随访监测。结果显示单标志物和标志物组合的灵敏度和特异度在不同研究间差异很大,尿液突变分析是有前景的无创诊断工具,但证据尚不足以被临床指南采纳。
要点
- 尿液突变标志物用于膀胱癌检测时,单标志物灵敏度1-85%、特异度84-100%,标志物组合灵敏度50-94%、特异度43-97%。
- 用于膀胱癌随访监测时,单标志物灵敏度0-85%、特异度66-100%,标志物组合灵敏度51-84%、特异度66-96%。
- 研究间异质性大,无法定量合并,需更多更强证据才能实现临床转化。
核心结论
- 尿液突变分析是膀胱癌无创诊断的有前景工具,但各研究间诊断准确性差异显著。
- 尿液膀胱癌突变标志物证据尚不足以被临床指南采纳。
研究设计与样本
- 系统综述,检索PubMed、Embase.com和Wiley/Cochrane Library,截至2019年10月31日。
- 共纳入25项研究进行定性分析,因研究异质性过大未做定量分析。
主要发现
- 膀胱癌检测:单突变标志物灵敏度1-85%、特异度84-100%;标志物组合灵敏度50-94%、特异度43-97%。
- 膀胱癌随访监测:单突变标志物灵敏度0-85%、特异度66-100%;标志物组合灵敏度51-84%、特异度66-96%。
关键数值与推荐
- 膀胱癌检测单标志物灵敏度范围1-85%、特异度范围84-100%。
- 膀胱癌检测标志物组合灵敏度范围50-94%、特异度范围43-97%。
- 膀胱癌随访监测单标志物灵敏度范围0-85%、特异度范围66-100%。
- 膀胱癌随访监测标志物组合灵敏度范围51-84%、特异度范围66-96%。
临床怎么用
- 尿液突变分析目前不宜作为膀胱癌诊断或随访的常规标准,需结合研究设计、人群、突变分析技术和尿液DNA差异谨慎解读。
- 联合不同分子检测可能克服当前尿液突变分析的不足。
局限性
- 研究异质性过大,无法进行定量分析。
- 研究设计、膀胱癌人群、突变分析技术和尿液DNA存在差异,影响结果解读。
- 证据强度和数量不足以支持临床指南采纳。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To systematically summarise the available evidence on urinary bladder cancer (BC) mutation markers. Gene mutations are expected to provide novel biomarkers for urinary BC diagnosis. To date, evidence on urinary BC mutation markers has not proven sufficient to be adopted by clinical guidelines. In the present systematic review, diagnostic accuracy of urinary mutation analysis is separately assessed for primary BC diagnosis (BC detection) and for follow-up of BC patients (BC surveillance). METHODS: A literature search (PubMed, Embase.com and Wiley/Cochrane Library) and systematic review was performed up to 31 October 2019. As studies were too heterogeneous, no quantitative analysis could be performed. RESULTS: In total, 25 studies were summarised by qualitative analysis. For BC detection, diagnostic accuracy differed considerably for single mutation markers (sensitivity 1-85%, specificity 84-100%), and for marker panels (sensitivity 50-94%, specificity 43-97%). Similarly, for BC surveillance, diagnostic accuracy was highly variable for single mutation markers (sensitivity 0-85%, specificity 66-100%), and for marker panels (sensitivity 51-84%, specificity 66-96%). CONCLUSION: Urinary mutation analysis showed to be a promising diagnostic tool for non-invasive BC diagnosis. Nonetheless, we observed substantial differences in diagnostic accuracy of urinary BC mutation markers among publications. To translate the data summarised in the present review to future clinical practice, heterogeneity in research design, BC population, mutation analysis technique and urinary DNA should be considered. Eventual clinical implementation of urinary BC mutation markers can only be achieved by collecting more and stronger evidence. Combining different molecular assays might overcome current shortcomings of urinary mutation analysis.
引用
- Hentschel AE, van der Toom EE, Vis AN, et al. A systematic review on mutation markers for bladder cancer diagnosis in urine. BJU Int. 2020. PMID: 32539176. doi:10.1111/bju.15137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。